First-in-human Safety and Immunogenicity Study of SCB-1022 and SCB-1033 in Healthy Older Adults

This phase 1 study will evaluate the safety, reactogenicity, and immunogenicity of 3 different dose levels of SCB-1022 and SCB-1033 in healthy adults aged 60-85 years.

Lead sponsor: Clover Biopharmaceuticals AUS Pty•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Contacts

Xuesong Pei, MD

CONTACT

+8618515445890 [email protected]

Related studies

COMPLETEDPhase 1

A Study on the Safety and Immunogenicity of Influenza, Respiratory Syncytial Virus, Human Metapneumovirus and Parainfluenza Vaccines in Adults 18 to 49 Years of Age.

NCT06850051 · Healthy Volunteers, Influenza Vaccination, and more

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: August 8, 2025Terms

Trial snapshot

StatusRECRUITING

PhasePHASE1

Enrollment192

Start dateJun 2025

Last updatedAug 8, 2025

Condition

Respiratory Syncytial Virus Vaccination Human Metapneumovirus Vaccination Parainfluenza Vaccination

Locations shown

Fusion Clinical Research

Adelaide, Southern Australia

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 8, 2025Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions